Fortrea Holdings (FTRE) Net Income towards Common Stockholders (2022 - 2026)
Fortrea Holdings (FTRE) posted Net Income towards Common Stockholders of -$23.6 million for Q1 2026, down 285.83% on a QoQ basis from $12.7 million in Q4 2024.
Fortrea Holdings (FTRE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Fortrea Holdings' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$23.6 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.6 million (up 34.08% YoY) and the FY2024 annual result came in at -$57.0 million, down 976.92% from the prior year.
- Net Income towards Common Stockholders was -$23.6 million for Q1 2026 at Fortrea Holdings, down from $12.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $66.4 million in Q2 2022 and bottomed at -$39.1 million in Q2 2024.
- A 4-year average of $3.3 million and a median of -$1.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 315.25% in 2024, while the deepest fall reached 774.14% in 2024.
- Fortrea Holdings' Net Income towards Common Stockholders stood at -$13.6 million in 2022, then surged by 56.62% to -$5.9 million in 2023, then jumped by 315.25% to $12.7 million in 2024, then plunged by 285.83% to -$23.6 million in 2026.
- Business Quant data shows FTRE's Net Income towards Common Stockholders at -$23.6 million in Q1 2026, $12.7 million in Q4 2024, and -$9.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Fortrea Holdings | 1.79 Bn | 1.64 Bn | 123.60 Mn | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2024 | 12.70 Mn |
| Sep 30, 2024 | -9.40 Mn |
| Jun 30, 2024 | -39.10 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Dec 31, 2023 | -5.90 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 4.50 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |